FINtick - a prospective multicenter study on tick-borne infections in finland

NCT ID NCT07897825

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 27, 2026 · Last updated Oct 28, 2026 · Updated 1 time

Summary

Ticks in Finland can carry several microbes that may infect humans. The best known tick-borne diseases are Lyme borreliosis and tick-borne encephalitis (TBE). In recent years, scientists have also found other microbes in Finnish ticks, such as Anaplasma, Rickettsia, Neoehrlichia, Borrelia miyamotoi, and Babesia. Infections caused by these microbes are called emerging tick-borne diseases. Climate change may also increase the number of ticks and expand their range further north. This could lead to more tick-borne diseases in the future. The public health impact of these emerging infections is still unclear. Some of them may cause severe illness, especially in people with weakened immune systems or without a spleen. However, we still know little about how common these infections are, how they develop in the body, and what symptoms they cause. Some people may have no symptoms, while others may become seriously ill. Good diagnostic tests are also lacking. More knowledge is also needed about Lyme borreliosis and TBE. Some forms of Lyme disease, such as arthritis, heart inflammation, or eye problems, may be underdiagnosed. In addition, TBE cases have increased in Finland in recent years. This study will examine the symptoms, recovery, and quality of life of patients with these infections. Another goal is to improve laboratory diagnostics. Current tests for Lyme disease and TBE mainly detect antibodies. These tests cannot always tell when the infection occurred or distinguish a past Lyme borreliosis infection from a current one. This also makes it difficult to detect reinfections in Lyme borreliosis or TBE-infections in vaccinated individuals. By collecting samples from patients, we aim to develop better diagnostic methods. The main goal of the study is to improve knowledge about tick-borne diseases in Finland. We will study how common emerging infections are, what symptoms they cause, and whether people can have more than one tick-borne infection at the same time. We will also examine how the immune system responds to these infections and how this relates to disease severity and recovery. This study includes both children and adults who are being examined for a suspected tick-borne disease. Participants will be followed for six months using questionnaires at initiation, one, three, and six months. Blood samples and other samples, depending on the patient's symptoms, will be collected together with routine clinical samples. The samples will be analyzed to detect tick-borne pathogens and antibodies against them. Molecular tests (PCR) will look for the genetic material of the microbes. Researchers will also search for new biological markers of these diseases and study the immune response using advanced laboratory methods. The study will be conducted in collaboration with the SWETICK study.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 850 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2025

Expected to finish

Dec 2034

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Medical history: tick exposure, tick bite, splenectomy, immunosuppressive treatment (e.g. anti-CD20 or other biological/immunomodulatory drugs, cortisone corresponding to \>10 mg prednisolone/day, chemotherapy, hematologic malignancy, other malignancy, rheumatologic disease) Symptoms/clinical signs: fever after tick bite, fever of unknown origin, skin rashes (single/multiple erythema migrans, lymphocytoma, acrodermatitis chronica atrophicans or other), venous thrombosis, repeated thrombophlebitis, vasculitis, meningitis, encephalitis, myelitis, cranial nerve palsy, radiculitis, peripheral nerve involvement, mono-/oligoarthritis, carditis, ocular or otogenic disturbances of uncertain origin where medical history includes recent tick bite. Laboratory findings in combination with suspicion of tick-borne disease: leukopenia, thrombocytopenia, anemia, elevated liver enzymes, slightly elevated erythrocyte sedimentation rate and/or C-reactive protein, pleocytosis in CSF or synovial fluid.

Ages

1 year and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Clinical suspicion of tick-borne disease. Exclusion criteria 1. Prisoners 2. Adults who are unable to decide, unless next of kin gives consent. 3. Patients, who cannot attend the first follow-up visit or phone call. 4. Patients, who are not willing to give a blood sample at the initiation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anaplasmosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Helsinki University Central Hospital

    RECRUITING

    Helsinki, 00029, Finland

  • Turku University Hospital

    RECRUITING

    Turku, 20521, Finland

  • Ålands hälso- och sjukcård ÅHS

    NOT_YET_RECRUITING

    Mariehamn, 22111, Finland

More trials for these conditions

Other studies related to the condition(s) this trial covers.